Newsletter Subject

4 Healthcare Megatrends for Investors by Kevin Cook

From

zacks.com

Email Address

profit4u@zacks.com

Sent On

Sat, Apr 22, 2017 12:01 PM

Email Preheader Text

4 Healthcare Megatrends for Investors By: Kevin Cook April 22, 2017 --------------------------------

[ZACKS Weekend Wisdom] 4 Healthcare Megatrends for Investors By: Kevin Cook April 22, 2017 --------------------------------------------------------------- When you think about investing to powerfully grow your money into the future, what giant long-term trends come to mind first? Certainly anything on the cutting edge of technology does -- from mobile, the cloud, and AI to robotics, alternative energy, and autonomous cars. But do you know what sector is bigger than technology and has trounced it by 3 times since 1999? Healthcare. And it offers just as much innovation, if not more -- with more diversification. If you are investing for the future, you need exposure to the healthcare sector to grow truly life-changing wealth. Opportunity Disguised But what about the impending "repeal and replace" of Obamacare and all the Washington saber-rattling over drug prices? Don't these make the sector "un-investable?" To the contrary, any policy moves offer only more opportunity in the 750 companies and 12 industries to choose from. And bigger picture, healthcare profits are still being driven by four big forces that won't stop for another decade at least. The 4 Megatrend Drivers of Healthcare Profits 1) Boomer Power: An aging population living longer means more care is needed into the "active 90s!" The demographic trends are clear: US and global populations are aging, as the Millennial baby boom may not be rivaled any time soon. Plus, people are living longer on average just because of improving economic standards, the quality of food, water, and medical care, and an awareness of health dangers like smoking. More . . . . [Notice to Zacks Members]( We are approaching what could be the investment opportunity of a lifetime. A new medical breakthrough has the potential to impact humanity on a scale that compares to the discovery of microbes and the introduction of vaccines. Zacks has just launched an initiative to target maximum profits from it. Gains could rival Incyte's leap of +951% in 6 years and Intuitive Surgical's explosion of +4,237% in 13 years. You're invited to be among the first to see our recommendations. Don't delay: access to this information closes Sunday, April 23. [Take Advantage Now >>]( This adds up to a big increase in the number of people living into their nineties. And that means more innovative care will be needed from several medical industries, including pharmaceuticals, cardiovascular technologies, neurological treatments, hospital equipment and instruments, biotechnology, and cancer research discoveries. 2) Science Power: The breakthroughs in genetics and technology are creating new life-saving and life-enhancing companies as I write. The age of genetics has ushered in unprecedented advances in scientific and medical research. We have gone from understanding and battling disease with scalpels and poisonous chemotherapies to treating cancer with targeted genetic breakthroughs and vaccines created from one's own immune system. This megatrend is nowhere near slowing down as companies, investors, and charities pour billions of dollars every year into new R&D to cure everything from heart and digestive ailments to pediatric and neuro-degenerative diseases. 3) Earnings Power: The follow-on from all that R&D are new products and solutions creating new channels of sales and profits. In 2016, the healthcare sector was responsible for over 40% of the earnings in the S&P 500, bigger than the financial, energy, and telecom sectors combined. And the strength of this profit engine is only enhanced by its diversity across hundreds of companies and a dozen space-age industries. The beauty of this wealth of investing opportunities is that when one area is out of favor due to political or regulatory headwinds, there are always three or four other industries creating dynamic sales and profit growth. 4) M&A Power: The big Pharma companies need to keep their pipelines full and avoid the revenue drops created by "patent cliffs." During this bull market, over $500 billion in deals have been done, mostly by big drug companies buying emerging biotech plays for 50-100% takeout premiums. One of my favorite biotech investments of the past few years was a company called Medivation, which got snatched up by Pfizer for $14 billion in 2016 -- but not before a bidding war was fought by some of the biggest names in pharma, forcing Pfizer to pay top dollar. While the pace of M&A may slow down from the frenzy we've seen the past few years, it will always be a positive force driving values in the sector -- especially if any tax reform policy unleashes a tidal wave of overseas corporate cash onto US shores. The Power of Vision These 4 megatrends don't look like they will stop in this decade. And probably not in the next one either! So make sure you have a long-term investing plan to capitalize on them. I know I'll be looking for the next Intuitive Surgical, which made new all-time highs this week and handed early investors a 4,200% return since June of 2000. If you'd like to target big gains like this, I invite you to join me inside Zacks' newest investment portfolio, [Healthcare Innovators.]( The confluence of the megatrends above are setting up what may be the most exciting investment opportunity of our lifetimes. Healthcare Innovators is designed to capitalize on these powerful forces and hand investors some of the biggest gains they've ever seen. Now, picking the best stocks in this sector requires a considerable amount of research. But if you make the right calls, the reward can be phenomenal. But you don't have to follow FDA filings or subscribe to medical journals. That's my job! Healthcare Innovators enables you to piggy-back on my in-depth research. I've kept a close eye on 3 companies at the forefront of the next wave of cancer treatment, what the National Cancer Institute has called "a class of living drugs." These companies could change the world. I reveal them and a number of other promising stocks positioned to capitalize on one or more of the megatrends we've talked about. You can be among the first to see these picks, by clicking the link below. Please note: We must limit the number of investors who share this information. Access closes Sunday, April 23. [Look into Healthcare Innovators right now >>]( Good Investing, Kevin Cook Kevin, Senior Stock Strategist at Zacks, is a leading expert in biotech and medical stocks. He now provides commentary and recommendations for Zacks' new investment portfolio, [Healthcare Innovators](. Follow Us: Manage Your Newsletter Subscriptions [Update Preferences]( [Update Your Profile]( [Unsubscribe All]( [Feedback]( [Send to a Friend]( This free resource is being sent by [Zacks.com]( to our subscribers. We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. [www.zacks.com/disclaimer]( Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, brokerage, market making or asset management activities of any securities. Visit [www.zacks.com/performance]( for information about the performance numbers displayed in this press release. Zacks Emails If you would prefer to not receive future profit-producing emails from [Zacks.com]( the primary purpose of which is the commercial advertisement or promotion of a commercial product or service, then please [click here]( and confirm your request. If you have trouble with the unsubscribe link, please email support@zacks.com . Zacks Investment Research, Inc. 10 S. Riverside Plaza, Suite 1600 Chicago, IL 60606 [Zacks] You are registered to receive this "Weekend Wisdom" e-mail newsletter at {EMAIL}

Marketing emails from zacks.com

View More
Sent On

07/12/2024

Sent On

07/12/2024

Sent On

05/12/2024

Sent On

04/12/2024

Sent On

04/12/2024

Sent On

02/12/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.